Unraveling the role of FoxOs in bone-Insights from mouse models

Bone

Volumn 49, Issue 3, 2011, Pages 319-327

  Almeida, Maria ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Aging; Osteoblasts; Osteoclasts; Reactive oxygen species; Wnt signaling

Indexed keywords

GROWTH FACTOR; INSULIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR FOXO4; UNCLASSIFIED DRUG;

AGING; BONE DEVELOPMENT; BONE DISEASE; BONE METABOLISM; BONE REMODELING; BONE STRESS; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; HOMEOSTASIS; HORMONE ACTION; MESENCHYMAL STEM CELL; MOUSE STRAIN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; BONE AND BONES; FORKHEAD TRANSCRIPTION FACTORS; HOMEOSTASIS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MODELS, ANIMAL; OSTEOBLASTS; OSTEOCLASTS; OXIDATION-REDUCTION; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 79960575561     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.05.023     Document Type: Review

References (140)

1. Greer E.L., Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005, 24:7410-7425.
2. Jacobs F.M., van der Heide L.P., Wijchers P.J., Burbach J.P., Hoekman M.F., Smidt M.P. FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J Biol Chem 2003, 278:35959-35967.
3. Arden K.C. FOXO animal models reveal a variety of diverse roles for FOXO transcription factors. Oncogene 2008, 27:2345-2350.
4. Puig O., Mattila J. Understanding forkhead box class O function: lessons from Drosophila melanogaster. Antioxid Redox Signal 2011, 14:635-647.
5. Partridge L., Bruning J.C. Forkhead transcription factors and ageing. Oncogene 2008, 27:2351-2363.
6. Sahin E., DePinho R.A. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010, 464:520-528.
7. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956, 11:298-300.
8. Muller F.L., Lustgarten M.S., Jang Y., Richardson A., Van Remmen H. Trends in oxidative aging theories. Free Radic Biol Med 2007, 43:477-503.
9. Nakamura H., Nakamura K., Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 1997, 15:351-369.
10. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408:239-247.
11. Kenyon C. A conserved regulatory system for aging. Cell 2001, 105:165-168.
12. Almeida M., Han L., Martin-Millan M., Plotkin L.I., Stewart S.A., Roberson P.K., et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007, 282:27285-27297.
13. Syed F.A., Modder U.I., Roforth M., Hensen I., Fraser D.G., Peterson J.M., et al. Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. J Bone Miner Res 2010, 25:2438-2446.
14. Halloran B.P., Ferguson V.L., Simske S.J., Burghardt A., Venton L.L., Majumdar S. Changes in bone structure and mass with advancing age in the male C57BL/6J mouse. J Bone Miner Res 2002, 17:1044-1050.
15. Iida H., Fukuda S. Age-related changes in bone mineral density, cross-sectional area and strength at different skeletal sites in male rats. J Vet Med Sci 2002, 64:29-34.
16. Jilka R.L., Almeida M., Ambrogini E., Han L., Roberson P.K., Weinstein R.S., et al. Decreased oxidative stress and greater bone anabolism in the aged, as compared to the young, murine skeleton by parathyroid hormone. Aging Cell 2010, 9:851-867.
17. Lean J.M., Davies J.T., Fuller K., Jagger C.J., Kirstein B., Partington G.A., et al. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest 2003, 112:915-923.
18. Jagger C.J., Lean J.M., Davies J.T., Chambers T.J. Tumor necrosis factor-alpha mediates osteopenia caused by depletion of antioxidants. Endocrinology 2005, 146:113-118.
19. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002, 415:45-53.
20. De Boer J., Andressoo J.O., de Wit J., Huijmans J., Beems R.B., van Steeg H., et al. Premature aging in mice deficient in DNA repair and transcription. Science 2002, 296:1276-1279.
21. Ambrogini E., Almeida M., Martin-Millan M., Paik J., dePinho R., Han L., et al. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab 2010, 11:136-146.
22. Rached M.T., Kode A., Xu L., Yoshikawa Y., Paik J.H., DePinho R.A., et al. FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab 2010, 11:147-160.
23. Medema R.H., Kops G.J., Bos J.L., Burgering B.M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404:782-787.
24. Tran H., Brunet A., Grenier J.M., Datta S.R., Fornace A.J., DiStefano P.S., et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002, 296:530-534.
25. Ramaswamy S., Nakamura N., Sansal I., Bergeron L., Sellers W.R. A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2002, 2:81-91.
26. Kops G.J., Dansen T.B., Polderman P.E., Saarloos I., Wirtz K.W., Coffer P.J., et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002, 419:316-321.
27. Nemoto S., Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002, 295:2450-2452.
28. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
29. Dijkers P.F., Medema R.H., Lammers J.W., Koenderman L., Coffer P.J. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000, 10:1201-1204.
30. Greer E.L., Brunet A. FOXO transcription factors in ageing and cancer. Acta Physiol (Oxf) 2008, 192:19-28.
31. Calnan D.R., Brunet A. The FoxO code. Oncogene 2008, 27:2276-2288.
32. de Keizer P., Burgering B., Dansen T.B. FOXO as a sensor, mediator and regulator of redox signaling. Antioxid Redox Signal 2010, 14(6):1093-1106.
33. Obsil T., Obsilova V. Structural basis for DNA recognition by FOXO proteins. Biochim Biophys Acta 2010, [Epub ahead of print]. 10.1016/j.bbamcr.2010.11.025.
34. Huang H., Tindall D.J. Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochim Biophys Acta 2011, Epub ahead of print. 10.1016/j.bbamcr.2011.01.007.
35. Asada S., Daitoku H., Matsuzaki H., Saito T., Sudo T., Mukai H., et al. Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal 2007, 19:519-527.
36. Yang J.Y., Zong C.S., Xia W., Yamaguchi H., Ding Q., Xie X., et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008, 10:138-148.
37. Singh A., Ye M., Bucur O., Zhu S., Tanya S.M., Rabinovitz I., et al. Protein phosphatase 2A reactivates FOXO3a through a dynamic interplay with 14-3-3 and AKT. Mol Biol Cell 2010, 21:1140-1152.
38. Yan L., Lavin V.A., Moser L.R., Cui Q., Kanies C., Yang E. PP2A regulates the pro-apoptotic activity of FOXO1. J Biol Chem 2008, 283:7411-7420.
39. van der H.A., Burgering B.M. Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol 2007, 8:440-450.
40. Essers M.A., Weijzen S., Vries-Smits A.M., Saarloos I., de Ruiter N.D., Bos J.L., et al. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 2004, 23:4802-4812.
41. Lehtinen M.K., Yuan Z., Boag P.R., Yang Y., Villen J., Becker E.B., et al. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 2006, 125:987-1001.
42. Wang M.C., Bohmann D., Jasper H. JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell 2005, 121:115-125.
43. Oh S.W., Mukhopadhyay A., Svrzikapa N., Jiang F., Davis R.J., Tissenbaum H.A. JNK regulates lifespan in Caenorhabditis elegans by modulating nuclear translocation of forkhead transcription factor/DAF-16. Proc Natl Acad Sci U S A 2005, 102:4494-4499.
44. Sunayama J., Tsuruta F., Masuyama N., Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 2005, 170:295-304.
45. Lee Y.H., Giraud J., Davis R.J., White M.F. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003, 278:2896-2902.
46. Bi W., Xiao L., Jia Y., Wu J., Xie Q., Ren J., et al. c-Jun N-terminal kinase enhances MST1-mediated pro-apoptotic signaling through phosphorylation at serine 82. J Biol Chem 2010, 285:6259-6264.
47. Choi J., Oh S., Lee D., Oh H.J., Park J.Y., Lee S.B., et al. Mst1-FoxO signaling protects naive T lymphocytes from cellular oxidative stress in mice. PLoS One 2009, 4:e8011.
48. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
49. van der H.A., Vries-Smits A.M., Brenkman A.B., van Triest M.H., van den B.N., Colland F., et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol 2006, 8:1064-1073.
50. Brenkman A.B., de Keizer P.L., van den Broek N.J., Jochemsen A.G., Burgering B.M. Mdm2 induces mono-ubiquitination of FOXO4. PLoS One 2008, 3:e2819.
51. Frescas D., Valenti L., Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005, 280:20589-20595.
52. Kitamura Y.I., Kitamura T., Kruse J.P., Raum J.C., Stein R., Gu W., et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab 2005, 2:153-163.
53. Zhao Y., Yang J., Liao W., Liu X., Zhang H., Wang S., et al. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol 2010, 12:665-675.
54. Dansen T.B., Smits L.M., van Triest M.H., de Keizer P.L., van Leenen D., Koerkamp M.G., et al. Redox-sensitive cysteines bridge p300/CBP-mediated acetylation and FoxO4 activity. Nat Chem Biol 2009, 5:664-672.
55. Edwards J.R., Zainabadi K., Lwin S.T., Elefteriou E., Munoz S., Moore M.M., Guarente L., Mundy G.R. The longevity gene SIRT-1 independently controls both osteoblast and osteoclast function. J Bone Miner Res 2008, 23:S28.
56. van der Vos K.E., Coffer P.J. FOXO-binding partners: it takes two to tango. Oncogene 2008, 27:2289-2299.
57. Seoane J., Le H.V., Shen L., Anderson S.A., Massague J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 2004, 117:211-223.
58. Kitamura T., Kitamura Y.I., Funahashi Y., Shawber C.J., Castrillon D.H., Kollipara R., et al. A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. J Clin Invest 2007, 117:2477-2485.
59. Dowell P., Otto T.C., Adi S., Lane M.D. Convergence of peroxisome proliferator-activated receptor gamma and Foxo1 signaling pathways. J Biol Chem 2003, 278:45485-45491.
60. Armoni M., Harel C., Karni S., Chen H., Bar-Yoseph F., Ver M.R., et al. FOXO1 represses peroxisome proliferator-activated receptor-gamma1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem 2006, 281:19881-19891.
61. Nakae J., Kitamura T., Kitamura Y., Biggs W.H., Arden K.C., Accili D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell 2003, 4:119-129.
62. Li P., Lee H., Guo S., Unterman T.G., Jenster G., Bai W. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 2003, 23:104-118.
63. Fan W., Yanase T., Morinaga H., Okabe T., Nomura M., Daitoku H., et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor. J Biol Chem 2007, 282:7329-7338.
64. Huang H., Muddiman D.C., Tindall D.J. Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem 2004, 279:13866-13877.
65. Ikonen T., Palvimo J.J., Janne O.A. Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 1997, 272:29821-29828.
66. Ma Q., Fu W., Li P., Nicosia S.V., Jenster G., Zhang X., et al. FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol 2009, 23:213-225.
67. Schuur E.R., Loktev A.V., Sharma M., Sun Z., Roth R.A., Weigel R.J. Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. J Biol Chem 2001, 276:33554-33560.
68. Zhao H.H., Herrera R.E., Coronado-Heinsohn E., Yang M.C., Ludes-Meyers J.H., Seybold-Tilson K.J., et al. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem 2001, 276:27907-27912.
69. Zou Y., Tsai W.B., Cheng C.J., Hsu C., Chung Y.M., Li P.C., et al. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res 2008, 10:R21.
70. Morelli C., Lanzino M., Garofalo C., Maris P., Brunelli E., Casaburi I., et al. Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells. Mol Cell Biol 2010, 30:857-870.
71. Yang S., Xu H., Yu S., Cao H., Fan J., Ge C., et al. FOXO1 mediates IGF1/insulin regulation of osteocalcin expression by antagonizing RUNX2 in osteoblasts. J Biol Chem 2011, [Epub ahead of print]. 10.1074/jbc.M110.197905.
72. Teixeira C.C., Liu Y., Thant L.M., Pang J., Palmer G., Alikhani M. Foxo1, a novel regulator of osteoblast differentiation and skeletogenesis. J Biol Chem 2010, 285:31055-31065.
73. Zhang H., Pan Y., Zheng L., Choe C., Lindgren B., Jensen E.D., et al. FOXO1 Inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011, 71:3257-3267.
74. Essers M.A., Vries-Smits L.M., Barker N., Polderman P.E., Burgering B.M., Korswagen H.C. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 2005, 308:1181-1184.
75. Almeida M., Han L., Martin-Millan M., O'Brien C.A., Manolagas S.C. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 2007, 282:27298-27305.
76. Furuyama T., Kitayama K., Shimoda Y., Ogawa M., Sone K., Yoshida-Araki K., et al. Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem 2004, 279:34741-34749.
77. Hosaka T., Biggs W.H., Tieu D., Boyer A.D., Varki N.M., Cavenee W.K., et al. Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A 2004, 101:2975-2980.
78. Cheng Z., White M.F. Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal 2011, 14:649-661.
79. Robertson R.P., Harmon J.S. Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 2006, 41:177-184.
80. Miyamoto K., Araki K.Y., Naka K., Arai F., Takubo K., Yamazaki S., et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007, 1:101-112.
81. Marinkovic D., Zhang X., Yalcin S., Luciano J.P., Brugnara C., Huber T., et al. Foxo3 is required for the regulation of oxidative stress in erythropoiesis. J Clin Invest 2007, 117:2133-2144.
82. Obsil T., Obsilova V. Structure/function relationships underlying regulation of FOXO transcription factors. Oncogene 2008, 27:2263-2275.
83. Tothova Z., Kollipara R., Huntly B.J., Lee B.H., Castrillon D.H., Cullen D.E., et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007, 128:325-339.
84. Paik J.H., Kollipara R., Chu G., Ji H., Xiao Y., Ding Z., et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 2007, 128:309-323.
85. Paik J.H., Ding Z., Narurkar R., Ramkissoon S., Muller F., Kamoun W.S., et al. FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell 2009, 5:540-553.
86. Renault V.M., Rafalski V.A., Morgan A.A., Salih D.A., Brett J.O., Webb A.E., et al. FoxO3 regulates neural stem cell homeostasis. Cell Stem Cell 2009, 5:527-539.
87. Sengupta A., Molkentin J.D., Paik J.H., DePinho R.A., Yutzey K.E. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem 2011, 286:7468-7478.
88. Hsu C.P., Zhai P., Yamamoto T., Maejima Y., Matsushima S., Hariharan N., et al. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation 2010, 122:2170-2182.
89. Sundaresan N.R., Gupta M., Kim G., Rajamohan S.B., Isbatan A., Gupta M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest 2009, 119:2758-2771.
90. Giorgio M., Migliaccio E., Orsini F., Paolucci D., Moroni M., Contursi C., et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005, 122:221-233.
91. Migliaccio E., Giorgio M., Mele S., Pelicci G., Reboldi P., Pandolfi P.P., et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999, 402:309-313.
92. Trinei M., Berniakovich I., Beltrami E., Migliaccio E., Fassina A., Pelicci P., et al. P66Shc signals to age. Aging (Albany NY) 2009, 1:503-510.
93. Almeida M., Han L., Ambrogini E., Bartell S.M., Manolagas S.C. Oxidative stress stimulates apoptosis and activates NF-kappaB in osteoblastic cells via a PKCbeta/p66shc signaling cascade: counter regulation by estrogens or androgens. Mol Endocrinol 2010, 24:2030-2037.
94. Tothova Z., Gilliland D.G. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 2007, 1:140-152.
95. Southgate R.J., Neill B., Prelovsek O., El Osta A., Kamei Y., Miura S., et al. FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle. J Biol Chem 2007, 282:21176-21186.
96. Rached M.T., Kode A., Silva B.C., Jung D.Y., Gray S., Ong H., et al. FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest 2010, 120:357-368.
97. Clemens T.L., Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res 2010, 26:677-680.
98. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008, 8:157-168.
99. Backesjo C.M., Li Y., Lindgren U., Haldosen L.A. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 2006, 21:993-1002.
100. Mizutani K., Ikeda K., Kawai Y., Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 1998, 253:859-863.
101. Biswas D.K., Singh S., Shi Q., Pardee A.B., Iglehart J.D. Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE 2005, 2005:e27.
102. Adler A.S., Sinha S., Kawahara T.L., Zhang J.Y., Segal E., Chang H.Y. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev 2007, 21:3244-3257.
103. De Bosscher K., Vanden Berghe W., Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006, 25:6868-6886.
104. Smith W.W., Norton D.D., Gorospe M., Jiang H., Nemoto S., Holbrook N.J., et al. Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity. J Cell Biol 2005, 169:331-339.
105. Hu M.C., Lee D.F., Xia W., Golfman L.S., Ou-Yang F., Yang J.Y., et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004, 117:225-237.
106. Hoogeboom D., Essers M.A., Polderman P.E., Voets E., Smits L.M., Burgering B.M. Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. J Biol Chem 2008, 283:9224-9230.
107. Liu H., Fergusson M.M., Wu J.J., Rovira I.I., Liu J., Gavrilova O., et al. Wnt signaling regulates hepatic metabolism. Sci Signal 2011, 4. ra6.
108. Schneider C., Porter N.A., Brash A.R. Routes to 4-hydroxynonenal: fundamental issues in the mechanisms of lipid peroxidation. J Biol Chem 2008, 283:15539-15543.
109. Almeida M., Ambrogini E., Han L., Manolagas S.C., Jilka R.L. Increased lipid oxidation causes oxidative stress, increased PPAR{gamma} expression and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem 2009, 284:27438-27448.
110. Kang S., Bennett C.N., Gerin I., Rapp L.A., Hankenson K.D., MacDougald O.A. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein α and peroxisome proliferator-activated receptor γ. J Biol Chem 2007, 282:14515-14524.
111. Okamura M., Kudo H., Wakabayashi K., Tanaka T., Nonaka A., Uchida A., et al. COUP-TFII acts downstream of Wnt/beta-catenin signal to silence PPARgamma gene expression and repress adipogenesis. Proc Natl Acad Sci U S A 2009, 106:5819-5824.
112. Sharma C., Pradeep A., Wong L., Rana A., Rana B. Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem 2004, 279:35583-35594.
113. Ambrogini E., Han L., Bartell S., Warren A., Shelton R., Vyas K., Deloose A., Weinstein R., O'Brien C., Manolagas S., Almeida M. Deletion of the FoxO1, 3 and 4 genes from committed osteoblast progenitors expressing osterix increases Wnt signaling and bone mass. J Bone Min Res 2010, 25:S23.
114. Bennett C.N., Longo K.A., Wright W.S., Suva L.J., Lane T.F., Hankenson K.D., et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 2005, 102:3324-3329.
115. Babij P., Zhao W., Small C., Kharode Y., Yaworsky P.J., Bouxsein M.L., et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 2003, 18:960-974.
116. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289-312.
117. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846-855.
118. Lambeth J.D. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004, 4:181-189.
119. Woo H.A., Yim S.H., Shin D.H., Kang D., Yu D.Y., Rhee S.G. Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling. Cell 2010, 140:517-528.
120. Garrett I.R., Boyce B.F., Oreffo R.O., Bonewald L., Poser J., Mundy G.R. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990, 85:632-639.
121. Levasseur R., Barrios R., Elefteriou F., Glass D.A., Lieberman M.W., Karsenty G. Reversible skeletal abnormalities in gamma-glutamyl transpeptidase-deficient mice. Endocrinology 2003, 144:2761-2764.
122. Bai X.C., Lu D., Liu A.L., Zhang Z.M., Li X.M., Zou Z.P., et al. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J Biol Chem 2005, 280:17497-17506.
123. Lean J.M., Jagger C.J., Kirstein B., Fuller K., Chambers T.J. Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 2005, 146:728-735.
124. Ha H., Kwak H.B., Lee S.W., Jin H.M., Kim H.M., Kim H.H., et al. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp Cell Res 2004, 301:119-127.
125. Lee N.K., Choi Y.G., Baik J.Y., Han S.Y., Jeong D.W., Bae Y.S., et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005, 106:852-859.
126. Ishii K.A., Fumoto T., Iwai K., Takeshita S., Ito M., Shimohata N., et al. Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 2009, 15:259-266.
127. Srinivasan S., Koenigstein A., Joseph J., Sun L., Kalyanaraman B., Zaidi M., et al. Role of mitochondrial reactive oxygen species in osteoclast differentiation. Ann N Y Acad Sci 2010, 1192:245-252.
128. Ambrogini E., Bartell S., Han L., Zhao H., Warren A., Shelton R., Qiu X., Goellner J., O'Brien C., Almeida Maria, Manolagas S. Gain of FoxO function in osteoclast precursors and their progeny decreases osteoclastogenesis and increases BMD in mice. J Bone Miner Res 2010, 25:S15.
129. Sugatani T., Hruska K.A. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005, 280:3583-3589.
130. Kawamura N., Kugimiya F., Oshima Y., Ohba S., Ikeda T., Saito T., et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One 2007, 2:e1058.
131. Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H., et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999, 4:1041-1049.
132. Reszka A.A., Halasy-Nagy J.M., Masarachia P.J., Rodan G.A. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999, 274:34967-34973.
133. Jang S.W., Yang S.J., Srinivasan S., Ye K. Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J Biol Chem 2007, 282:30836-30844.
134. Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., Delaisse J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005, 65:9943-9952.
135. He X., Andersson G., Lindgren U., Li Y. Resveratrol prevents RANKL-induced osteoclast differentiation of murine osteoclast progenitor RAW 264.7 cells through inhibition of ROS production. Biochem Biophys Res Commun 2010, 401:356-362.
136. Shakibaei M., Buhrmann C., Mobasheri A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-{kappa}B ligand (RANKL) activation of NF-{kappa}B signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem 2011, 286:11492-11505.
137. Su J.L., Yang C.Y., Zhao M., Kuo M.L., Yen M.L. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem 2007, 282:19385-19398.
138. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
139. Holmen S.L., Zylstra C.R., Mukherjee A., Sigler R.E., Faugere M.C., Bouxsein M.L., et al. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005, 280:21162-21168.
140. Ferron M., Wei J., Yoshizawa T., Del Fattore A., DePinho R.A., Teti A., et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 2010, 142:296-308.